Last reviewed · How we verify
NGM282
At a glance
| Generic name | NGM282 |
|---|---|
| Sponsor | NGM Biopharmaceuticals, Inc |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) (PHASE2)
- Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3) (PHASE2)
- A Study of NGM282 in Patients With Primary Sclerosing Cholangitis (PHASE2)
- Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) (PHASE2)
- Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM) (PHASE2)
- Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects (PHASE1)
- Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function (PHASE1)
- Study of Aldafermin (NGM282) in Participants With Impaired Renal Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NGM282 CI brief — competitive landscape report
- NGM282 updates RSS · CI watch RSS
- NGM Biopharmaceuticals, Inc portfolio CI